

# Douglas B Johnson

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5454152/publications.pdf](https://exaly.com/author-pdf/5454152/publications.pdf)

Version: 2024-02-01

280  
papers

31,871  
citations

9389

74  
h-index

6192

160  
g-index

294  
all docs

294  
docs citations

294  
times ranked

46397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. <i>JCO Clinical Cancer Informatics</i> , 2024, , .	2.2	3
2	Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care. <i>Cancer Journal (Sudbury, Mass )</i> , 2024, 30, 126-131.	2.0	2
3	Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. <i>Nature Communications</i> , 2024, 15, .	13.2	1
4	Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study. <i>Cancer Letters</i> , 2024, 596, 217001.	7.3	1
5	Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1514-1525.	3.6	11
6	Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs. <i>Bioinformatics</i> , 2023, 39, .	4.2	5
7	Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. <i>European Journal of Cancer</i> , 2023, 181, 188-197.	2.9	6
8	Corticosteroids and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 2580-2587.	7.2	21
9	Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 427-428.	27.6	5
10	Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 3712-3723.	15.4	17
11	Multi-organ landscape of therapy-resistant melanoma. <i>Nature Medicine</i> , 2023, 29, 1123-1134.	30.1	14
12	Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 2278-2285.	30.1	33
13	Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities. <i>Immunological Reviews</i> , 2023, 318, 157-166.	6.1	8
14	Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. <i>Nature Medicine</i> , 2023, 29, 3100-3110.	30.1	15
15	The role of plastic surgery in the immune checkpoint inhibitor era. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 893-939.	1.1	0
16	Adjuvant Pembrolizumab versus IFN-2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	14.2	44
17	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.9	29
18	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	27.6	56

#	ARTICLE	IF	CITATIONS
19	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		42
20	Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients. Npj Precision Oncology, 2022, 6, 6.	5.5	4
21	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. BMC Cancer, 2022, 22, 38.	2.6	5
22	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	27.6	469
23	Clinical Models to Define Response and Survival With Anti-“PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	15.4	52
24	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. British Journal of Dermatology, 2022, 187, 401-410.	1.7	25
25	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America, 2022, 42, 285-305.	1.9	4
26	Primed for toxicity: CD4+ T cells and immune checkpoint inhibitors. Med, 2022, 3, 155-156.	4.2	4
27	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discovery, 2022, 12, 303-330.	14.2	28
28	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. Investigational New Drugs, 2022, 40, 1051-1065.	2.7	6
29	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute’s Cancer Therapy Evaluation Program. Journal of Clinical Oncology, 2022, 40, 3439-3452.	15.4	30
30	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. American Journal of Clinical Dermatology, 2022, 23, 707-717.	6.9	4
31	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist, 2022, 27, 778-789.	4.1	3
32	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		8
33	Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precision Oncology, 2022, , .	3.2	15
34	Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 2022, 127, 1726-1732.	6.6	5
35	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. Current Treatment Options in Oncology, 2022, 23, 1428-1442.	3.1	4
36	Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 2022, 28, 2364-2373.	30.1	63

#	ARTICLE	IF	CITATIONS
37	T cells specific for Î±-myosin drive immunotherapy-related myocarditis. <i>Nature</i> , 2022, 611, 818-826.	36.2	138
38	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	14.2	171
39	A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis. <i>Oncologist</i> , 2021, 26, e505-e507.	4.1	2
40	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	2.0	5
41	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	7.2	107
42	Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2021, 39, 122.	16.8	36
43	Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma. <i>Oncologist</i> , 2021, 26, e333-e335.	4.1	3
44	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	9.6	56
45	Surveillance for Metastatic Disease. , 2021, , 153-171.		0
46	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.2	58
47	The correlation between learning interest and mathematics achievement in grade VII SMP PGRI Bengkulu. <i>Journal of Physics: Conference Series</i> , 2021, 1731, 012051.	0.4	0
48	Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 583-590.	2.6	5
49	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	3.1	33
50	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. <i>Journal of Investigative Medicine</i> , 2021, 69, 888-892.	1.8	12
51	Supportive care for new cancer therapies. <i>Current Opinion in Oncology</i> , 2021, 33, 287-294.	2.5	6
52	Tilsolelimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	14.2	38
53	Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 295-313.	3.2	10
54	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	2.9	47

#	ARTICLE	IF	CITATIONS
55	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	9.6	203
56	Efficacy and Safety of Trametinib in <scp>Non-V600 <i>BRAF</i></scp> Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 731-e1498.	4.1	23
57	Chronic Immune-Related Adverse Events Following Adjuvant Anti-“PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	7.3	128
58	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		39
59	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	10.7	60
60	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	2.9	18
61	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	3.2	11
62	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. <i>European Journal of Cancer</i> , 2021, 148, 36-47.	2.9	45
63	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.8	116
64	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		378
65	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. <i>Molecular Cancer</i> , 2021, 20, 85.	20.2	26
66	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		105
67	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.9	17
68	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		25
69	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 281-294.	0.6	5
70	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	2.9	17
71	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.3	160
72	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-“PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	7.2	89

#	ARTICLE	IF	CITATIONS
73	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , 2021, 22, e343-e344.	10.8	2
74	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.9	7
75	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events – Reply. <i>JAMA Oncology</i> , 2021, 7, 1574-1575.	7.3	2
76	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 155, 291-293.	2.9	21
77	Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute – Designated Comprehensive Cancer Center. <i>Oncologist</i> , 2021, 26, e1962-e1970.	4.1	11
78	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 956-966.	1.2	69
79	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Clinical Hematology International</i> , 2021, 3, 96.	1.9	8
80	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>OncImmunology</i> , 2021, 10, 1875639.	4.8	36
81	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		38
82	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	3.6	17
83	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	2.9	10
84	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.3	89
85	239 – Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study. , 2021, , .		0
86	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	6.0	34
87	812 – Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells. , 2021, , .		1
88	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 786046.	4.9	26
89	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. <i>American Journal of Transplantation</i> , 2020, 20, 879-883.	4.9	99
90	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	4.1	14

#	ARTICLE	IF	CITATIONS
91	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	15.4	144
92	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, e602-e605.	4.1	36
93	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	10.9	44
94	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	10.8	84
95	Impact of body composition on outcomes from anti-PD1 + anti-CTLA-4 treatment in melanoma. , 2020, 8, e000821.		63
96	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	2.3	22
97	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020, 28, 6175-6181.	2.3	17
98	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	2.3	15
99	Conserved Interferon- $\gamma$ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	16.8	231
100	COVID-19: the Emerging Role of Medical Student Involvement. <i>Medical Science Educator</i> , 2020, 30, 1641-1643.	1.6	13
101	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6107-6110.	2.3	17
102	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	2.3	32
103	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020, 28, 6111-6117.	2.3	24
104	Pandemic Medicine: The Management of Advanced Melanoma During COVID-19. <i>Melanoma Management</i> , 2020, 7, MMT45.	0.6	7
105	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	2.3	17
106	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	16.8	27
107	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 851-855.	3.3	43
108	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. <i>Oncologist</i> , 2020, 25, 696-701.	4.1	80

#	ARTICLE	IF	CITATIONS
109	Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R. <i>Oncogenesis</i> , 2020, 9, 44.	4.8	21
110	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	12.1	1,443
111	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
112	Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. <i>Cancer</i> , 2020, 126, 3448-3455.	4.1	22
113	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	5.9	92
114	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	3.3	24
115	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
116	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		42
117	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	2.5	99
118	Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. <i>European Journal of Cancer</i> , 2020, 135, 211-220.	2.9	43
119	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		74
120	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	3.6	28
121	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. <i>European Respiratory Journal</i> , 2020, 55, 2000038.	7.5	22
122	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	2.6	17
123	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	0.5	273
124	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	7.2	57
125	Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 3803-3818.	7.2	23
126	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	5.0	16



#	ARTICLE	IF	CITATIONS
127	429â€¦Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. , 2020, , .		13
128	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to antiâ€œPD-1 immunotherapy. Journal of Clinical Investigation, 2020, 130, 2570-2586.	8.2	155
129	MEK inhibitors in non-V600 BRAF mutations and fusions. Oncotarget, 2020, 11, 3900-3903.	2.1	10
130	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
131	Targeted Therapy in Advanced Melanoma. , 2019, , 667-686.		0
132	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Science Translational Medicine, 2019, 11, .	13.4	84
133	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology, 2019, 5, 1195.	7.3	462
134	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.1	141
135	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	9.3	298
136	Correlates of response and outcomes with talimogene laherperpvec. Journal of Surgical Oncology, 2019, 120, 558-564.	1.7	18
137	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 123, 112-115.	2.9	21
138	Longer Survival With Antiâ€œProgrammed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Associationâ€œIn Reply. JAMA Oncology, 2019, 5, 1642.	7.3	0
139	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	15.4	89
140	Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678.	5.6	189
141	A phase 2 study of glembatumumab vedotin, an antibodyâ€œdrug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer, 2019, 125, 1113-1123.	4.1	51
142	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	3.7	338
143	Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Molecular Cancer Research, 2019, 17, 1842-1853.	3.5	11
144	Abatacept for Severe Immune Checkpoint Inhibitorâ€œAssociated Myocarditis. New England Journal of Medicine, 2019, 380, 2377-2379.	30.1	321

#	ARTICLE	IF	CITATIONS
145	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		260
146	Immunotherapy in Older Adults with Cancer. Current Oncology Reports, 2019, 21, 56.	4.1	19
147	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		3
148	Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncology, 2019, 5, 906.	7.3	87
149	Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist, 2019, 24, 584-588.	4.1	113
150	Adverse Events Associated With Immune Checkpoint Inhibitors-Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1219.	7.0	1
151	Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. European Journal of Cancer, 2019, 113, 10-13.	2.9	24
152	Targeting tissue factor in advanced solid tumours. Lancet Oncology, The, 2019, 20, 318-319.	10.8	0
153	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	3.3	30
154	Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4583-4591.	7.6	35
155	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	4.3	56
156	Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. Oncologist, 2019, 24, 1495-1496.	4.1	0
157	Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. Cancer Immunology Research, 2019, 7, 1755-1759.	3.3	21
158	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. Oncologist, 2019, 24, 872-876.	4.1	41
159	Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology, 2019, 20, 81.	3.1	29
160	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		714
161	Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2019, 42, 221-227.	2.5	23
162	Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?. Clinical Cancer Research, 2019, 25, 1452-1454.	7.2	34

#	ARTICLE	IF	CITATIONS
163	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. <i>Cancer Immunology Research</i> , 2019, 7, 86-99.	3.3	30
164	Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2392-2402.	7.2	320
165	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	7.2	59
166	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>Oncolmmunology</i> , 2019, 8, e1524695.	4.8	46
167	Tolerance and efficacy of <i>BRAF</i> plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019, 125, 884-891.	4.1	45
168	Targeted Therapies for <i>BRAF</i> -Mutant Metastatic Melanoma. , 2019, , 1-19.		0
169	Tiivistelmä. Investing in Youth, , .	0.0	0
170	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	4.1	145
171	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology, The</i> , 2018, 19, 310-322.	10.8	521
172	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 36-40.	2.0	79
173	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	36.2	283
174	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Oncolmmunology</i> , 2018, 7, e1438106.	4.8	56
175	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. <i>Lancet, The</i> , 2018, 391, 933.	12.1	660
176	<i>BRAF</i> internal deletions and resistance to <i>BRAF</i> / <i>MEK</i> inhibitor therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 432-436.	3.3	32
177	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	6.9	18
178	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018, 52, 207-215.	9.8	44
179	Long-Term Outcomes in Patients With <i>BRAF</i> V600E-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	15.4	204
180	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology, The</i> , 2018, 19, 1579-1589.	10.8	811

#	ARTICLE	IF	CITATIONS
181	Immune Checkpoint Inhibitor Toxicity in 2018. JAMA - Journal of the American Medical Association, 2018, 320, 1702.	7.0	211
182	Immune Checkpoint Inhibitor-Associated Myositis. Circulation, 2018, 138, 743-745.	9.3	150
183	Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care, 2018, 41, e150-e151.	9.1	90
184	Targeted Therapy in Advanced Melanoma. , 2018, , 1-20.		0
185	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. JAMA Oncology, 2018, 4, 1721.	7.3	1,788
186	Continued Poor Survival in Metastatic Uveal Melanoma. JAMA Ophthalmology, 2018, 136, 986.	2.6	12
187	Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clinical Cancer Research, 2018, 24, 6107-6109.	7.2	21
188	Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Lancet, The, 2018, 392, 384-385.	12.1	8
189	Toxicities and outcomes: Do steroids matter?. Cancer, 2018, 124, 3638-3640.	4.1	6
190	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 5250-5260.	7.2	128
191	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	7.2	277
192	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	2.9	15
193	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	5.0	137
194	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight, 2018, 3, .	5.0	32
195	Biomarkers for immune therapy in melanoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 120-126.	1.5	2
196	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 2017, 168, 542.	27.8	314
197	Cardiovascular Toxicities Associated with Cancer Immunotherapies. Current Cardiology Reports, 2017, 19, 21.	2.9	134
198	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. , 2017, 5, 1.		70

#	ARTICLE	IF	CITATIONS
199	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	4.1	273
200	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	3.3	43
201	Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. <i>Journal of Leukocyte Biology</i> , 2017, 102, 437-447.	3.3	75
202	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	2.5	85
203	Rationale for Harnessing the Abscopal Effect as Potential Treatment for Metastatic Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017, 57, 41-48.	0.7	9
204	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971.	4.1	153
205	Enabling A Genetically Informed Approach to Cancer Medicine: Evaluation of the Impact of Comprehensive Tumor Sequencing. <i>Personalized Medicine</i> , 2017, 14, 189-192.	1.4	0
206	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	30.1	1,134
207	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1705-1717.	3.9	60
208	Integrated genomic analyses reveal frequent <i>TERT</i> aberrations in acral melanoma. <i>Genome Research</i> , 2017, 27, 524-532.	5.6	127
209	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		115
210	Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. <i>Oncolimmunology</i> , 2017, 6, e1305535.	4.8	60
211	MDM2 Antagonists Counteract Drug-Induced DNA Damage. <i>EBioMedicine</i> , 2017, 24, 43-55.	6.0	13
212	Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. <i>Cancer Discovery</i> , 2017, 7, 1248-1265.	14.2	137
213	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.4	501
214	Immunotherapy for Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017, 57, 29-39.	0.7	10
215	PD-1/PD-L1 blockade in renal cell cancer. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 77-84.	3.2	28
216	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	3.2	3

#	ARTICLE	IF	CITATIONS
217	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>Oncolimmunology</i> , 2017, 6, e1344805.	4.8	152
218	When to Consider Alternatives to Front-Line Immune Therapies in Metastatic Melanoma. <i>Melanoma Management</i> , 2017, 4, 71-74.	0.6	0
219	Smoldering myocarditis following immune checkpoint blockade. , 2017, 5, 91.		159
220	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.2	51
221	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.2	279
222	Comparative analysis of the <i>GNAQ</i> , <i>GNA11</i> , <i>SF3B1</i> , and <i>EIF1AX</i> driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 470-473.	3.3	18
223	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	3.3	20
224	Update on immune therapy in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 799-808.	0.8	0
225	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	10.4	79
226	Responses to immune checkpoint inhibitors in nonagenarians. <i>Oncolimmunology</i> , 2016, 5, e1234572.	4.8	24
227	Advances in the Development of Intralesional Therapies for Melanoma. <i>Melanoma Management</i> , 2016, 3, 259-266.	0.6	5
228	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	36.2	306
229	Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 773-776.	4.6	5
230	Systems immune monitoring in cancer therapy. <i>European Journal of Cancer</i> , 2016, 61, 77-84.	2.9	40
231	Emerging targeted therapies for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 195-207.	2.4	22
232	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	3.3	433
233	A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 101-103.	3.3	11
234	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	4.1	309

#	ARTICLE	IF	CITATIONS
235	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	4.1	248
236	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	13.2	437
237	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		61
238	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	30.1	1,772
239	Treatment of elderly patients with melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 13-16.	0.6	0
240	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	3.3	95
241	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	7.3	552
242	Melanoma driver mutations and immune therapy. <i>Oncotarget</i> , 2016, 5, e1051299.	4.8	13
243	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	27.8	2,576
244	Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 474-480.	3.3	19
245	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <i>Current Oncology Reports</i> , 2016, 18, 6.	4.1	26
246	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. <i>Oncotarget</i> , 2015, 6, 2496-2508.	2.1	16
247	Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e122-e124.	15.4	104
248	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.9	283
249	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	16.8	306
250	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	3.3	151
251	Nivolumab in melanoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 97-106.	3.4	130
252	Melanoma and a Headache. <i>JAMA Oncology</i> , 2015, 1, 1167.	7.3	5

#	ARTICLE	IF	CITATIONS
253	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015, 3, 464-469.	3.3	94
254	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015, 1, 380.	7.3	67
255	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma. <i>Immunotherapy</i> , 2015, 7, 611-619.	2.0	146
256	Treatment of NRAS-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 15.	3.1	116
257	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	4.1	39
258	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. <i>Cell</i> , 2015, 162, 1271-1285.	27.8	536
259	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	2.1	12
260	Clinical Utility of BRAF-Targeted Therapy in Melanoma. <i>Cancer Drug Discovery and Development</i> , 2015, , 67-84.	0.0	0
261	Biomarkers in Melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.6	1
262	Adult Neuroblastoma Complicated by Increased Intracranial Pressure: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-5.	0.4	3
263	<i>Pneumocystis jirovecii</i> pneumonia following everolimus treatment of metastatic breast cancer. <i>Medical Mycology Case Reports</i> , 2014, 6, 34-36.	1.3	4
264	A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1918-1928.	3.7	86
265	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. <i>Clinical Cancer Research</i> , 2014, 20, 2264-2275.	7.2	61
266	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2014, 4, 80-93.	14.2	855
267	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> <sup>V600</sup> -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	15.4	176
268	Immune Checkpoint Inhibitors in NSCLC. <i>Current Treatment Options in Oncology</i> , 2014, 15, 658-669.	3.1	65
269	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	4.1	96
270	Molecular Pathways: Targeting <i>NRAS</i> in Melanoma and Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 4186-4192.	7.2	62



#	ARTICLE	IF	CITATIONS
271	BRAFV600E-Mutant Melanoma Presenting With Cardiac Involvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 611-615.	10.4	2
272	Management of â€˜pan-negativeâ€™ melanoma: current and emerging strategies. Melanoma Management, 2014, 1, 87-90.	0.6	0
273	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	3.3	102
274	Update on the Targeted Therapy of Melanoma. Current Treatment Options in Oncology, 2013, 14, 280-292.	3.1	47
275	Bird Species Diversity of the Mitidja Plain (Northern Algeria) with Emphasis on the Dynamics of Invasive and Expanding Species. Acrocephalus, 2013, 34, 13-26.	0.4	11
276	Follow-up Recommendations for Chest CT Scan Reports of Incidental Pulmonary Nodules. Chest, 2012, 141, 280-281.	0.9	1
277	La valeur ajoutÃ©e de la notation dans les opÃ©rations de titrisation. Revue D'economie FinanciÃ©re, 2000, 59, 85-98.	0.1	0
278	Reply to S. Rossi et al and P. Palassin et al. Journal of Clinical Oncology, 0, , .	15.4	0
279	Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis. Cancer Immunology Research, 0, , OF1-OF2.	3.3	0
280	Immune checkpoint inhibitor infusion times and clinical outcomes in patients with melanoma. Oncologist, 0, , .	4.1	0